CUL5 and plasma cell myeloma: Because endothelial cells are an essential barrier in all cancer types and viral infections, CUL5 may be an important new biomarker for predicting a specific response to thalidomide and possibly other anti-angiogenic drugs used clinically to treat disorders that include multiple myeloma and HIV infections.